José Baselga

117.7k citations

484 papers · 46.7k indexed · 26 hit papers · h-index 98

Impact in

Oncology top 0.01%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
Otorhinolaryngology top 0.05%
- Head and Neck Cancer Studies

Papers in

Oncology 332
- HER2/EGFR in Cancer Research 188
- Cancer Treatment and Pharmacology 149
Cancer Research 110
- Breast Cancer Treatment Studies 52
- Cancer Genomics and Diagnostics 49

Co-authors: David M. Hyman Maurizio Scaltriti Neil Vasan J. Giralt Paul M. Harari James A. Bonner Roger B. Cohen David Raben
Journals: Journal of Clinical Oncology (159 papers)Cancer Research (81 papers)Annals of Oncology (37 papers)Clinical Cancer Research (21 papers)European Journal of Cancer (14 papers)
Partner nations: United States Spain United Kingdom

In The Last Decade

José Baselga

474 papers receiving 45.7k citations

Hit Papers

15 papers align trajectories log scale

A view on drug resistance in cancer 2019 · 1.9k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2019 Nature
2018 Journal of Clinical Oncology
2018 Nature Genetics
2017 The Lancet Oncology
2017 Clinical Cancer Research
2017 The Lancet
2017 Cell stem cell
2015 JAMA Oncology
2015 New England Journal of Medicine
2014 Annals of Oncology
2013 Nature Genetics
2013 Science
2013 The Lancet Oncology
2013 Advances in Therapy
2011 Journal of Clinical Oncology
2009 The Lancet Oncology
2009 Journal of Clinical Oncology
2008 Journal of Clinical Investigation
2008 Cancer Research
2007 Journal of Clinical Oncology
2006 New England Journal of Medicine
2006 Cancer Research
2006 Clinical Cancer Research
2005 Journal of Clinical Oncology
1998 Journal of Clinical Oncology
1996 Journal of Clinical Oncology

Peers

Countries citing papers authored by José Baselga

Since Specialization

Citations

This map shows the geographic impact of José Baselga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by José Baselga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites José Baselga more than expected).

Fields of papers citing papers by José Baselga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by José Baselga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by José Baselga. The network helps show where José Baselga may publish in the future.

Co-authors

The 25 scholars most cited alongside José Baselga, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with José Baselga Line = papers co-authored together José Baselga links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer Clinical Cancer Research ·Maura N. Dickler, Cristina Saura, Donald Richards, Ian E. Krop, Andrés Cervantes, Philippe L. Bédard, Manish R. Patel, Lajos Pusztai, Mafalda Oliveira, G. Da Molin, Na Cui, Timothy R. Wilson, Thomas J. Stout, Michael C. Wei, Jerry Y. Hsu, José Baselga	2018	57
2	Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. Journal of Clinical Oncology ·José Baselga, Susan Dent, Javier Cortés, Young‐Hyuck Im, Véronique Dièras, Nadia Harbeck, Ian E. Krop, Sunil Verma, Timothy R. Wilson, Huan Jin, Lijia Wang, Frauke Schimmöller, Jerry Y. Hsu, Jing He, Michelino De Laurentiis, Pamela Drullinsky, William Jacot	2018	105
3	Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition Cancer Research ·Rona Yaeger, Zhan Yao, David M. Hyman, Jaclyn F. Hechtman, Efsevia Vakiani, HuiYong Zhao, Wenjing Su, Lu Wang, Andrew Joelson, Andrea Cercek, José Baselga, Elisa de Stanchina, Leonard B. Saltz, Michael F. Berger, David B. Solit, Neal Rosen	2017	60
4	Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors Cancer Discovery ·Dejan Juric, Ian E. Krop, Ramesh K. Ramanathan, Timothy R. Wilson, Joseph A. Ware, Sandra Sanabria Bohórquez, Heidi Savage, Deepak Sampath, Laurent Salphati, Ray Lin, Huan Jin, Hema Parmar, Jerry Y. Hsu, Daniel D. Von Hoff, José Baselga	2017	120
5	Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists Cancer Discovery ·Weiyi Toy, Hazel M. Weir, Pedram Razavi, Mandy Lawson, Anne U. Goeppert, Anne Marie Mazzola, Aaron Smith, Joanne Wilson, Christopher J. Morrow, Wai Lin Wong, Elisa de Stanchina, Kathryn E. Carlson, 侯金松, Sharmeen Uddin, Zhiqiang Li, Sean W. Fanning, John A. Katzenellenbogen, Geoffrey L. Greene, José Baselga, Sarat Chandarlapaty	2016	269
6	Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer Cancer Discovery ·Xiuning Le, Emile Jean Guillaume von Baumhauer, Pedram Razavi, Daniel J. Treacy, Flora Luo, Mahmoud Ghandi, Pau Castel, Maurizio Scaltriti, José Baselga, Levi A. Garraway	2016	97
7	Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors Clinical Cancer Research ·秀真堀内, Ana M. Figueiredo, Pau Castel, Laura Ruiz Martín, Raquel Sofia Lima Pereira, Ana Angulo‐Urarte, Maria Milà‐Guasch, Francesc Viñals, José Baselga, Oriol Casanovas, Mariona Graupera	2016	34
8	Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer Clinical Cancer Research ·José Baselga, Gail D. Lewis Phillips, Sunil Verma, Jungsil Ro, Jens Huober, Alice E. Guardino, Meghna Samant, Steve Olsen, Sanne Lysbet de Haas, Mark D. Pegram	2016	150
9	Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations Clinical Cancer Research ·Zachary S. Zumsteg, Natasha Morse, Steffen Ronalter, Gaorav P. Gupta, Daniel S. Higginson, Nancy Y. Lee, Luc G.T. Morris, Ian Ganly, BİLGE Suat, Simon N. Powell, Christine H. Chung, Maurizio Scaltriti, José Baselga	2015	68
10	Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors Clinical Cancer Research ·Kyriakos P. Papadopoulos, Josep Tabernero, Ben Markman, Amita Patnaik, Anthony W. Tolcher, José Baselga, Weiliang Shi, Coumaran Égile, Rodrigo Ruiz-Soto, Alexander Laird, Dale Miles, Patricia LoRusso	2014	87
11	Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy Clinical Cancer Research ·Cristina Saura, Johanna C. Bendell, Guy Jérusalem, William Johns, Qinhua Ru, Stefan Buck, David Mills, Adam Baumgardner, Ana Bosch, Ander Urruticoechea, J. Thaddeus Beck, Emmanuelle di Tomaso, David Sternberg, Cristian Massacesi, Samit Hirawat, Luc Dirix, José Baselga	2014	110
12	A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases Clinical Cancer Research ·Josep Tabernero, María Elena Elez, María Herranz‐López, 左近淑郎, Ludmila Prudkin, Jordi Andreu, José M. Mateos, Mohammad Shane Alam, May Han, James Gifford, M. Arkuszewski, Wei Yin, Shefali Agarwal, Philip Komarnitsky, José Baselga	2014	30
13	Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2 JNCI Journal of the National Cancer Institute ·Michael Gnant, José Baselga, Hope S. Rugo, Shinzaburo Noguchi, Howard A. Burris, Martine Piccart, Gabriel N. Hortobágyi, Janice F. Eakle, Hirofumi Mukai, Hiroji Iwata, Matthias Geberth, Lowell L. Hart, Peyman Hadji, Mona El-Hashimy, Dong Meibin, Tetiana Taran, Tarek Sahmoud, David Lebwohl, Mario Campone, Kathleen I. Pritchard	2013	77
14	Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition Science ·Min Yu, Aditya Bardia, Ben S. Wittner, Shannon L. Stott, Malgorzata E. Smas, David T. Ting, Steven J. Isakoff, Jordan C. Ciciliano, Editors Revue de Synthèse, Ajay M. Shah, Kyle Concannon, Maria Donaldson Collier, Lecia V. Sequist, Elena F. Brachtel, Dennis C. Sgroi, José Baselga, Sridhar Ramaswamy, Mehmet Toner, Daniel A. Haber, Shyamala Maheswaran Hit paper breakdown →	2013	1928
15	Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors Clinical Cancer Research ·Ferry A.L.M. Eskens, Francisco Javier Ramos, Herman Burger, James P. O’Brien, Adelaida Piera, Maja J.A. de Jonge, Yoshiharu Mizui, Erik A.C. Wiemer, Luís Alves, José Baselga, Josep Tabernero	2013	195
16	Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer Journal of Clinical Oncology ·José Baselga, Patricia Gómez, Richard Greil, Sofía Braga, Miguel Ángel Climent, Andrew Wardley, Bella Kaufman, Salomon M. Stemmer, António Pêgo, Arlene Chan, J. Goeminne, Marie-Pascale Graas, Megan Kennedy, Eva María Ciruelos Gil, Andreas Schneeweiß, Angela Zubel, Jutta Groos, Helena Melezínková, Ahmad Awada	2013	298
17	Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2 V659E Mutation Cancer Discovery ·Violeta Serra, Ana Vivancos, Xosé S. Puente, Enriqueta Felip, Daniel Silberschmidt, Ginevra Caratù, Josep-Lluís Parra, Leticia De Mattos‐Arruda, Judit Grueso, Javier Hernández‐Losa, Joaquı́n Arribas, Ludmila Prudkin, Paolo Nucíforo, Maurizio Scaltriti, Joan Seoane, José Baselga	2013	33
18	Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788 Clinical Cancer Research ·José Baselga, Alain C. Mita, Patrick Schöffski, Herlinde Dumez, Federico Rojo, Josep Tabernero, Clifford DiLea, William Mietlowski, H. Falke, W.J. Sowter, Margaret Dugan, Kathryn Parker, Eric Walk, A. van Oosterom, Erika Martinelli, Chris H. Takimoto	2012	14
19	Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer Cancer Discovery ·Ashish Juvekar, Laura N. Burga, Hai Hu, Elaine P. Lunsford, Yasir H. Ibrahim, Judith Balmañà, Anbazhagan Rajendran, Antonella Papa, Katherine Spencer, Costas A. Lyssiotis, Caterina Nardella, Pier Paolo Pandolfi, José Baselga, Ralph Scully, John M. Asara, Lewis C. Cantley, Gerburg M. Wulf	2012	336
20	NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations Cancer Research ·Violeta Serra, Ben Markman, Maurizio Scaltriti, Pieter J.A. Eichhorn, Vanesa Valero, Marta Guzmán, María Luisa Botero, Elisabeth Llonch, Francesco Atzori, Serena Di Cosimo, Michel Maira, Carlos Garcı́a-Echeverrı́a, Josep Lluís Parra, Joaquı́n Arribas, José Baselga Hit paper breakdown →	2008	626

About José Baselga

José Baselga is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Genetics, having authored 484 papers that have together received 46.7k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (188 papers), Cancer Treatment and Pharmacology (149 papers), Advanced Breast Cancer Therapies (116 papers), PI3K/AKT/mTOR signaling in cancer (107 papers), Lung Cancer Treatments and Mutations (71 papers), Monoclonal and Polyclonal Antibodies Research (59 papers), Breast Cancer Treatment Studies (52 papers) and Cancer Genomics and Diagnostics (49 papers). The work is most often cited by research in Oncology (25.8k citations), Otorhinolaryngology (3.3k citations), Cancer Research (9.8k citations), Pulmonary and Respiratory Medicine (14.1k citations) and Genetics (3.8k citations). José Baselga has collaborated with scholars based in United States, Spain and United Kingdom. Frequent co-authors include David M. Hyman, Maurizio Scaltriti, Neil Vasan, J. Giralt, Paul M. Harari, James A. Bonner, Roger B. Cohen, David Raben, Christopher U. Jones and Eric K. Rowinsky. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, Clinical Cancer Research and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact